Clinical trial
Canadian Assessment of the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
NCT01142583 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Canadian Assessment of the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- August 31, 2009
- Enrollment
- 192 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.